|
1
|
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
|
Sci Transl Med
|
2011
|
2.04
|
|
2
|
Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
|
Biol Blood Marrow Transplant
|
2006
|
1.06
|
|
3
|
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.
|
Autophagy
|
2010
|
1.04
|
|
4
|
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.
|
Blood
|
2003
|
0.98
|
|
5
|
Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.
|
Mol Ther
|
2008
|
0.86
|
|
6
|
Host-based Th2 cell therapy for prolongation of cardiac allograft viability.
|
PLoS One
|
2011
|
0.85
|
|
7
|
Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo.
|
Stem Cells
|
2015
|
0.83
|
|
8
|
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection.
|
Mol Cancer Ther
|
2009
|
0.80
|
|
9
|
Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
|
Biol Blood Marrow Transplant
|
2004
|
0.79
|
|
10
|
Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells.
|
Cytotherapy
|
2013
|
0.78
|